Cretostimogene grenadenorepvec
BCG-naïve High-Risk NMIBC
Phase 3Active, not recruiting (PIVOT-005)
Key Facts
Indication
BCG-naïve High-Risk NMIBC
Phase
Phase 3
Status
Active, not recruiting (PIVOT-005)
Company
About CG Oncology
CG Oncology is a late-stage biopharma company with a mission to deliver innovative, bladder-sparing immunotherapies for patients with non-muscle invasive bladder cancer (NMIBC). Its lead asset, cretostimogene grenadenorepvec, an intravesical oncolytic immunotherapy, has garnered FDA Fast Track and Breakthrough Therapy designations and is in a pivotal Phase 3 program. The company's strategy is intensely focused on successfully commercializing this potential backbone therapy in a significant market with limited effective options for BCG-unresponsive patients.
View full company profile